AstraZeneca Aims To Grow Seroquel XR With Added Indications, Not Switches

AstraZeneca is looking to establish Seroquel XR, the sustained-release line extension of its atypical antipsychotic quetiapine, by adding unique indications rather than pushing to switch patients from immediate-release Seroquel